Glanton Ex Rel. ALCOA Prescription Drug Plan v. AdvancePCS Inc.

465 F.3d 1123, 2006 WL 2949169
CourtCourt of Appeals for the Ninth Circuit
DecidedOctober 16, 2006
Docket04-15328
StatusPublished
Cited by65 cases

This text of 465 F.3d 1123 (Glanton Ex Rel. ALCOA Prescription Drug Plan v. AdvancePCS Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Ninth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Glanton Ex Rel. ALCOA Prescription Drug Plan v. AdvancePCS Inc., 465 F.3d 1123, 2006 WL 2949169 (9th Cir. 2006).

Opinion

KOZINSKI, Circuit Judge.

We consider whether prescription drug plan participants who have suffered no judicially cognizable injury may sue their plans’ fiduciaries under the Employee Retirement Income Security Act of 1974 (“ERISA”).

Facts

AdvancePCS is a pharmacy benefits management company (PBM). PBMs manage prescription drug benefit programs and seek to reduce their clients’ drug costs by pooling claims and negotiating volume discounts with pharmaceutical companies. Among AdvancePCS’s clients are employee welfare benefit plans sponsored by ALCOA and K-Mart.

When AdvancePCS receives a prescription from one of the plan participants, it decides whether to buy the drug (preferably from a seller with whom it has negotiated a discount), reject the claim or switch the participant to another drug.

AdvancePCS pays for the drugs with plan assets after accounting for the participant’s co-payment. Plaintiffs allege that, in addition to earning fees from the plans, AdvancePCS has secretly been keeping the spread between what it charges the plans for drugs and what it pays suppliers — a practice plaintiffs claim violates ERISA.

Plaintiff Tommie Glanton works for ALCOA and is a member of its prescription drug plan. Plaintiff Tara Mackner was a member of the K-Mart plan, but ceased working for K-Mart after the suit was filed and thus no longer participates in its plan. 1

Plaintiffs sued AdvancePCS under ERISA for breach of fiduciary duty. The district court found that plaintiffs lacked standing. Plaintiffs appeal.

Analysis

1. ERISA authorizes plan participants to sue fiduciaries for losses the plan suffers from a breach of their duties. 29 U.S.C. §§ 1109, 1132(a). A plan fiduciary is defined as anyone who exerts “any discretionary authority ... respecting management of such [a] plan.” 29 U.S.C. § 1002(21)(A).

AdvancePCS easily fits this definition. In choosing whether to fill a prescription or shift a participant to a different drug, it exercises discretion over the plans’ assets. While AdvancePCS is not named as a plan fiduciary, the applicable section of ERISA makes no distinction between named and unnamed fiduciaries. See 29 U.S.C. § 1002(21)(A); see also Kayes v. Pac. Lumber, 51 F.3d 1449, 1458-61 (9th Cir.1995). It follows that plaintiffs here are authorized to sue AdvancePCS for breach of fiduciary duty.

2. Plaintiffs, nevertheless, cannot proceed unless they have Article III standing. See Raines v. Byrd, 521 U.S. 811, 820 n. 3, 117 S.Ct. 2312, 138 L.Ed.2d 849 (1997). They claim to meet the traditional standing requirements outlined by Lujan v. De *1125 fenders of Wildlife, 504 U.S. 555, 112 S.Ct. 2130, 119 L.Ed.2d 351 (1992). Alternatively, they contend that they have standing as congressionally authorized representatives of the injured plans.

To establish standing under Lu-jan, plaintiffs must show a likelihood that the injury they have suffered will be redressed by a favorable outcome to the litigation. Id. at 560-62, 112 S.Ct. 2130. Plaintiffs don’t claim they were denied benefits or received inferior drugs. Rather, they claim that AdvancePCS charged the plans too much for drugs, and that this caused the plans to demand higher co-payments and contributions from participants. Plaintiffs claim that, if their suit is successful, the plans’ drug costs will decrease, and that the plans might then reduce contributions or co-payments. But nothing would force ALCOA or K-Mart to do this, nor would any one-time award to the plans for past overpayments inure to the benefit of participants. ALCOA and K-Mart would be free to reduce their contributions or cease funding the plans altogether until any such funds were exhausted. There is no redressability, and thus no standing, where (as is the case here) any prospective benefits depend on an independent actor who retains “broad and legitimate discretion the courts cannot presume either to control or to predict.” ASARCO, Inc. v. Radish, 490 U.S. 605, 615, 109 S.Ct. 2037, 104 L.Ed.2d 696 (1989) (opinion of Kennedy, J.); see also Fernandez v. Brock, 840 F.2d 622, 627 (9th Cir.1988).

Other circuits that have considered this issue have reached the same conclusion. See Cent. States Se. & Sw. Areas Health & Welfare Fund v. Merck-Medco Managed Care, 433 F.3d 181, 201 (2d Cir.2005); Horvath v. Keystone Health Plan E., 333 F.3d 450, 455 (3d Cir.2003); Harley v. Minnesota Mining & Mfg., 284 F.3d 901, 906 (8th Cir.2002).

We therefore turn to plaintiffs’ argument that they have standing to bring this lawsuit as representatives of the plan. Plaintiffs rely heavily on Vermont Agency of Natural Resources v. United States ex rel. Stevens, 529 U.S. 765, 120 S.Ct. 1858, 146 L.Ed.2d 836 (2000), which upheld qui tam actions against an Article III standing challenge. Relators in qui tam actions are congressionally authorized to sue for redress of injuries suffered by the United States. Qui tam plaintiffs retain a percentage of the recovery; the rest goes to the United States. The issue in Vermont Agency was whether the fact that qui tam plaintiffs have suffered “no ... invasion” of any “legally protected right” precludes them from having Article III standing. Id. at 772-73, 120 S.Ct. 1858.

The Court concluded that the False Claims Act (FCA) “can reasonably be regarded as effecting a partial assignment of the Government’s damages claim” to the relator, and that an “adequate basis for the relator’s suit [could be found] in the doctrine that the assignee of a claim has standing to assert the injury in fact suffered by the assignor.” Id. at 773, 120 S.Ct. 1858. The Court noted “the long tradition of qui tam actions in England and the American Colonies,” and that it has “routinely” entertained suits by assignees. Id. at 773-74, 120 S.Ct. 1858.

We find the qui tam analogy inapt. Whereas qui tam actions have existed for centuries, there is no similar tradition of unharmed ERISA beneficiaries bringing suit on behalf of their plans. 2 More importantly, the FCA assigns relators a concrete *1126

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
465 F.3d 1123, 2006 WL 2949169, Counsel Stack Legal Research, https://law.counselstack.com/opinion/glanton-ex-rel-alcoa-prescription-drug-plan-v-advancepcs-inc-ca9-2006.